BACKGROUND & AIMS: Ubiquitination is a reversible protein modification involved in the major cellular processes that define cell phenotype and behaviour. Ubiquitin modifications are removed by a large family of proteases named deubiquitinases. The role of deubiquitinases in hepatic stellate cell (HSC) activation and their contribution to fibrogenesis are poorly defined. We have identified that the deubiquitinase ubiquitin C-terminal hydrolase 1 (UCHL1) is highly induced following HSC activation, determined its function in activated HSC and its potential as a therapeutic target for fibrosis. METHODS: Deubiquitinase expression was determined in day 0 and day 10 HSC. Increased UCHL1 expression was confirmed in human HSC and in an alcoholic liver disease (ALD) patient liver. The importance of UCHL1 in hepatic fibrosis was investigated in CCl4 and bile duct ligation injured mice using a pharmacological inhibitor (LDN 57444). The effects of UCHL1 inhibition on HSC proliferation were confirmed by Western blot and 3H thymidine incorporation. RESULTS: Here we report that pharmacological inhibition of UCHL1 blocks progression of established fibrosis in CCl4 injured mice. UCHL1 siRNA knockdown, LDN 57444 treatment, or HSC isolated from UCHL1(-/-) mice show attenuated proliferation in response to the mitogen, platelet-derived growth factor. Additionally, we observed changes in the phosphorylation of the cell cycle regulator retinoblastoma protein (Rb) in the absence of UCHL1 highlighting a potential mechanism for the reduced proliferative response. CONCLUSIONS: UCHL1 expression is highly upregulated upon HSC activation and is involved in the regulation of HSC proliferation. This study highlights therapeutic opportunities for pharmacological targeting of UCHL1 in chronic liver disease.
BACKGROUND & AIMS: Ubiquitination is a reversible protein modification involved in the major cellular processes that define cell phenotype and behaviour. Ubiquitin modifications are removed by a large family of proteases named deubiquitinases. The role of deubiquitinases in hepatic stellate cell (HSC) activation and their contribution to fibrogenesis are poorly defined. We have identified that the deubiquitinase ubiquitin C-terminal hydrolase 1 (UCHL1) is highly induced following HSC activation, determined its function in activated HSC and its potential as a therapeutic target for fibrosis. METHODS: Deubiquitinase expression was determined in day 0 and day 10 HSC. Increased UCHL1 expression was confirmed in human HSC and in an alcoholic liver disease (ALD) patient liver. The importance of UCHL1 in hepatic fibrosis was investigated in CCl4 and bile duct ligation injured mice using a pharmacological inhibitor (LDN 57444). The effects of UCHL1 inhibition on HSC proliferation were confirmed by Western blot and 3H thymidine incorporation. RESULTS: Here we report that pharmacological inhibition of UCHL1 blocks progression of established fibrosis in CCl4 injured mice. UCHL1 siRNA knockdown, LDN 57444 treatment, or HSC isolated from UCHL1(-/-) mice show attenuated proliferation in response to the mitogen, platelet-derived growth factor. Additionally, we observed changes in the phosphorylation of the cell cycle regulator retinoblastoma protein (Rb) in the absence of UCHL1 highlighting a potential mechanism for the reduced proliferative response. CONCLUSIONS: UCHL1 expression is highly upregulated upon HSC activation and is involved in the regulation of HSC proliferation. This study highlights therapeutic opportunities for pharmacological targeting of UCHL1 in chronic liver disease.
Authors: E Leroy; R Boyer; G Auburger; B Leube; G Ulm; E Mezey; G Harta; M J Brownstein; S Jonnalagada; T Chernova; A Dehejia; C Lavedan; T Gasser; P J Steinbach; K D Wilkinson; M H Polymeropoulos Journal: Nature Date: 1998-10-01 Impact factor: 49.962
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Naomi C Read; Alex Gutsol; Chet E Holterman; Anthony Carter; Josée Coulombe; Douglas A Gray; Chris R J Kennedy Journal: Biochim Biophys Acta Date: 2014-03-22
Authors: Yichin Liu; Hilal A Lashuel; Sungwoon Choi; Xuechao Xing; April Case; Jake Ni; Li-An Yeh; Gregory D Cuny; Ross L Stein; Peter T Lansbury Journal: Chem Biol Date: 2003-09
Authors: Josée Coulombe; Prasanna Gamage; Madison T Gray; Mei Zhang; Matthew Y Tang; John Woulfe; M Jill Saffrey; Douglas A Gray Journal: Front Aging Neurosci Date: 2014-06-19 Impact factor: 5.750
Authors: E Matuszczak; A Sankiewicz; W Debek; E Gorodkiewicz; R Milewski; A Hermanowicz Journal: Clin Exp Immunol Date: 2017-10-16 Impact factor: 4.330
Authors: Nattawadee Panyain; Aurélien Godinat; Thomas Lanyon-Hogg; Sofía Lachiondo-Ortega; Edward J Will; Christelle Soudy; Milon Mondal; Katie Mason; Sarah Elkhalifa; Lisa M Smith; Jeanine A Harrigan; Edward W Tate Journal: J Am Chem Soc Date: 2020-07-01 Impact factor: 15.419
Authors: Michele Vacca; Jack Leslie; Samuel Virtue; Brian Y H Lam; Olivier Govaere; Dina Tiniakos; Sophie Snow; Susan Davies; Kasparas Petkevicius; Zhen Tong; Vivian Peirce; Mette Juul Nielsen; Zsuzsanna Ament; Wei Li; Tomasz Kostrzewski; Diana Julie Leeming; Vlad Ratziu; Michael E D Allison; Quentin M Anstee; Julian L Griffin; Fiona Oakley; Antonio Vidal-Puig Journal: Nat Metab Date: 2020-06-08